CD274 and small cell lung carcinoma: Patients with LS-SCLC that showed no disease progression after standard chemoradiotherapy were assigned in a 1:1:1 manner to receive the PD-L1 inhibitor durvalumab plus tremelimumab, durvalumab alone, or placebo.